Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.52 |
| ▸ | NQO2 | P16083 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5146534 | 0.87 | MEN1 (0.48) | MTNR1AMTNR1BNQO2MEN1KMT2A | |
| SCHEMBL1309580 | 0.82 | MTNR1A (0.76) | MTNR1AMTNR1BNQO2MEN1KMT2A | |
| SCHEMBL4509981 | 0.82 | NQO2 (0.64) | MTNR1AMTNR1BNQO2MEN1KMT2A | |
| SCHEMBL3667836 | 0.82 | MEN1 (0.52) | MTNR1AMTNR1BNQO2MEN1KMT2A | |
| SCHEMBL6450630 | 0.82 | MTNR1A (0.50) | MTNR1AMTNR1BNQO2MEN1KMT2A | |
| SCHEMBL27973662 | 0.81 | GFER (0.54) | MTNR1AMTNR1BNQO2MEN1KMT2A | |
| SCHEMBL27973664 | 0.81 | MEN1 (0.51) | MTNR1AMTNR1BNQO2MEN1KMT2A | |
| Methyl Carbamate SCHEMBL6828082 | 0.78 | HTR2A (0.52) | MEN1KMT2A | |
| SCHEMBL25100772 | 0.78 | MEN1 (0.49) | MTNR1AMTNR1BNQO2MEN1KMT2A | |
| SCHEMBL11601895 | 0.78 | MTNR1A (0.71) | MTNR1AMTNR1BMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064701-A1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | UNIVERSIDAD DE GRANADA (ES) | 2025-02-27 | — | — | US | disclosed |
| US-20240050451-A1 | PRECISION CANNABINOID THERAPY FORMULATIONS AND METHODS OF USE | MDM ENTERPRISE SOLUTIONS INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-20230414470-A1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | UNIVERSIDAD DE GRANADA (ES) | 2023-12-28 | — | — | US | disclosed |
| US-20230031519-A1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | UNIVERSIDAD DE GRANADA (ES) | 2023-02-02 | — | — | US | disclosed |
| WO-2022067078-A1 | PRECISION CANNABINOID THERAPY FORMULATIONS AND METHODS OF USE | MDM ENTERPRISE SOLUTIONS INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-11234964-B2 | Use of melatonin for the treatment of tumors | UNIVERSIDAD DE GRANADA (ES) | 2022-02-01 | — | — | US | disclosed |
| US-20210106562-A1 | USE OF MELATONIN FOR THE TREATMENT OF TUMOURS | UNIVERSIDAD DE GRANADA (ES) | 2021-04-15 | — | — | US | disclosed |
| EP-3603635-A2 | USE OF MELATONIN FOR THE TREATMENT OF TUMOURS | Universidad de Granada (ES) | 2020-02-05 | — | — | EP | disclosed |
| EP-2926800-B1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | UNIV GRANADA (ES) | 2019-05-29 | — | — | EP | disclosed |
| US-20180311133-A1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | UNIVERSIDAD DE GRANADA (ES) | 2018-11-01 | — | — | US | disclosed |
| WO-2014083227-A1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | UNIVERSIDAD DE GRANADA (ES) | 2014-06-05 | — | — | WO | disclosed |
| EP-2702992-A1 | USE OF MELATONIN FOR TREATING AND/OR PREVENTING MUCOSITIS | Universidad de Granada (ES) | 2014-03-05 | — | — | EP | disclosed |
| WO-2013178587-A1 | USE OF N-ACETYL-5-METHOXYTRYPTAMINE OR ANALOGUES THEREOF, FOR PROMOTING THE MECHANISM OF IMPLANTATION OF THE EMBRYO AND RELATED COMPOSITIONS AND CULTURE MEDIA | MAXIA NICOLETTA (IT) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013057354-A1 | USE OF MELATONIN FOR TREATING AND/OR PREVENTING MUCOSITIS | UNIVERSIDAD DE GRANADA (ES) | 2013-04-25 | — | — | WO | disclosed |
| EP-0214254-B1 | MELATONIN COMPOSITIONS AND USES THEREOF | CELLENA (CELL ENGINEERING) A.G. (CH) | 1992-06-17 | — | — | EP | disclosed |
| US-4746674-A | Melatonin compositions and uses thereof | CELLENA (CELL ENGINEERING) AG (CH) | 1988-05-24 | — | — | US | disclosed |
| EP-0229131-A1 | USE OF MELATONIN OR RELATED COMPOUNDS FOR THE TREATMENT OF PSORIASIS | CELLENA (CELL ENGENEERING) A.G. (CH) | 1987-07-22 | — | — | EP | disclosed |
| EP-0214254-A1 | MELATONIN COMPOSITIONS AND USES THEREOF. | CELL ENG AG (CH) | 1987-03-18 | — | — | EP | disclosed |
| WO-1987000432-A2 | USE OF MELATONIN OR RELATED COMPOUNDS FOR THE TREATMENT OF PSORIASIS | CELLENA (CELL ENGINEERING) A.G. (CH) | 1987-01-29 | — | — | WO | disclosed |
| WO-1986005093-A2 | MELATONIN COMPOSITIONS AND USES THEREOF | CELLENA (CELL ENGINEERING) A.G. (CH) | 1986-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414470-A1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | NDUFA10, NDUFB10, TIMM10 | MTNR1A 60/4885MTNR1B 90/4885NQO2 194/4885 |
| US-20250064701-A1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | NDUFA10, NDUFB10, TIMM10 | MTNR1A 60/4885MTNR1B 90/4885NQO2 194/4885 |
| US-11234964-B2 | Use of melatonin for the treatment of tumors | MTNR1A, MTNR1B, MFN2 | MTNR1A 1/4885MTNR1B 2/4885NQO2 349/4885 |
| US-20210106562-A1 | USE OF MELATONIN FOR THE TREATMENT OF TUMOURS | MTNR1A, MTNR1B, MFN2 | MTNR1A 1/4885MTNR1B 2/4885NQO2 346/4885 |
| US-20180311133-A1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | NDUFA10, NDUFB10, TIMM10 | MTNR1A 60/4885MTNR1B 90/4885NQO2 194/4885 |
| US-20230031519-A1 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | NDUFA10, NDUFB10, TIMM10 | MTNR1A 60/4885MTNR1B 90/4885NQO2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.